Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section
Primary Purpose
Post Partum Haemorrhage
Status
Completed
Phase
Phase 1
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Misoprostol
Oxytocin
Oxytocin and Misoprostol
Sponsored by
About this trial
This is an interventional prevention trial for Post Partum Haemorrhage focused on measuring post partum haemorrhage at cesarean section
Eligibility Criteria
Inclusion Criteria:
- pregnant women at term (37-40 wks) gestation scheduled for either elective or emergency lower segment cesarean section
Exclusion Criteria:
- women with any risk factor
- associated with an increased risk of postpartum
- hemorrhage were excluded i.e. anemia (Hb8 g%), multiple gestation, antepartum hemorrhage,poly-hydramnios, two or more previous cesarean sections and/or a history of previous rupture uterus.
- current or previous history of significant disease including heart disease, liver, renal disorders or known coagulopathy
Sites / Locations
- Qazvin Medical University Science
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Misoprostol
Oxytocin
Oxytocin and Misoprostol
Arm Description
Outcomes
Primary Outcome Measures
changes in hemoglobin levels after delivery
Secondary Outcome Measures
Hemodynamic variables
Full Information
NCT ID
NCT01571323
First Posted
April 3, 2012
Last Updated
October 10, 2012
Sponsor
Qazvin University Of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT01571323
Brief Title
Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section
Study Type
Interventional
2. Study Status
Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Qazvin University Of Medical Sciences
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to demonstrate that the combined used of low dose of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin or misoprostol alone at cesarean sectionOne hundred fifty women with singleton term pregnancy undergoing elective or emergency lower segment cesarean section under spinal anesthesia were included in this study. The patients were randomly allocated to one of three groups of 50 each. The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate ,The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it) and the combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate . The main outcome measures were blood loss at cesarean section, change in hemoglobin levels, need for additional oxytocics and drug related side effects.The volume of blood in the suction bottle was measured, blood soaked sponges and added to volume from suction bottle. Hemoglobin values were determined both before surgery and 24 h following surgery. Hemodynamic variables were recorded every 5 minutes during surgery .The need for additional oxytocic therapy, operating time, infusion volume given intraoperatively, need for blood transfusion, side effects of study drug and any significant puerperal morbidity were also recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Partum Haemorrhage
Keywords
post partum haemorrhage at cesarean section
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Misoprostol
Arm Type
Active Comparator
Arm Title
Oxytocin
Arm Type
Active Comparator
Arm Title
Oxytocin and Misoprostol
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Intervention Description
The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
Intervention Type
Drug
Intervention Name(s)
Oxytocin and Misoprostol
Intervention Description
The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
Primary Outcome Measure Information:
Title
changes in hemoglobin levels after delivery
Time Frame
Hemoglobin values will be determined both before surgery and 24 h following surgery
Secondary Outcome Measure Information:
Title
Hemodynamic variables
Time Frame
every 5 minutes during surgery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
pregnant women at term (37-40 wks) gestation scheduled for either elective or emergency lower segment cesarean section
Exclusion Criteria:
women with any risk factor
associated with an increased risk of postpartum
hemorrhage were excluded i.e. anemia (Hb8 g%), multiple gestation, antepartum hemorrhage,poly-hydramnios, two or more previous cesarean sections and/or a history of previous rupture uterus.
current or previous history of significant disease including heart disease, liver, renal disorders or known coagulopathy
Facility Information:
Facility Name
Qazvin Medical University Science
City
Qazvin
ZIP/Postal Code
3419759811
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Learn more about this trial
Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section
We'll reach out to this number within 24 hrs